While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Often the biggest public companies, especially the technology giants, trade in the low-to-mid hundreds, all the way up to over $1,000 per share. At those steep prices, it’s pretty hard to get any decent share count leverage.

Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count. That can really help the decision-making process, especially when you are on to a winner, as you can always sell half and keep half.

[in-text-ad]

Every week, we screen our 24/7 Wall St. research database looking for stocks with Buy equivalent rating at major firms and priced under the $10 level (last week’s picks included BlackBerry and TiVo), and this week was no exception. We found five more stocks that could provide investors with some solid upside potential. While more suited for aggressive accounts, they could prove exciting additions to portfolios looking for solid alpha potential.

Callon Petroleum

This is a small-cap stock that Northland Securities favors. Callon Petroleum Co. (NYSE: CPE) is an independent oil and natural gas company that is engaged in the exploration, development, acquisition and production of oil and natural gas properties. The company focuses on the acquisition and development of unconventional oil and natural gas reserves in the Permian Basin.

Callon’s drilling activity focuses on the horizontal development of various prospective intervals in the Midland Basin, including multiple levels of the Wolfcamp formation and the Lower Spraberry shale. The company made a huge $570 million acquisition of 29,000 net acres last May, which more than doubled its Delaware Basin footprint.

Northland Securities has a price target of $10, while the Wall Street consensus target was last seen at $8.78. The stock was trading at $4.51 a share on Friday’s close.

Galmed Pharmaceuticals

This off-the-radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company that focuses on the development of the liver-targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis (NASH) for variable populations, as well as other liver-associated disorders.

Its Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring.

The analysts at Maxim have a towering $20 price objective, but the posted consensus target is even higher at $31.33. The shares were trading on Friday’s close at $5.23 apiece.

This stock has been blitzed this year but is showing signs it may have reached bottom, still offering aggressive accounts a timely entry point. Sientra Inc. (NASDAQ: SIEN) as a medical aesthetics company that engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments.

The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and Biocorneum. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device that uses consumable single-use bioTips.

[in-text-ad]

With breast implants under scrutiny, the company has told the FDA that the primary focus is upholding the highest levels of patient safety. Importantly, the totality of the firm’s clinical and real-world data, including its 10-year Post-Approval Cohort Study, which included almost 1,800 participants fully met FDA’s compliance requirements, and has confirmed the long-term safety and effectiveness of the company’s products.

Stephens has set its price target at $16. The consensus figure is $15.30, and shares were trading at $7.10 as the week came to a close.

Tellurian

This company could be poised for big gains as liquefied natural gas (LNG) exporting continues to ramp higher. Tellurian Inc. (NASDAQ: TELL) is an LNG development company headquartered in Houston, Texas. The company plans to develop a 27.6 metric tonnes per annum, LNG terminal with five plants near Lake Charles, Louisiana, as well as upstream assets and pipeline infrastructure.

The initial phase likely will include three plants (16.6 metric tonnes per annum, capacity). The Driftwood project will be financed by equity customers and partners, as well as project debt financing. Tellurian will own 28% to 42% of Driftwood Holdings and 100% of Tellurian Marketing.

The company announced earlier this year that the U.S. Federal Energy Regulatory Commission issued the final Environmental Impact Statement for Driftwood LNG, an export facility and associated 96-mile pipeline (Driftwood project), proposed near Lake Charles on the U.S. Gulf Coast. The first LNG from Driftwood is expected in 2023.

The Raymond James $12 price objective compares with the $11.47 consensus target price. The share price ended the past week at $7.94.

Viking Therapeutics

This small-cap biotech could have monster upside potential. Viking Therapeutics Inc. (NASDAQ: VKTX) focuses on the development of therapies for metabolic and endocrine disorders. Its clinical program, VK5211, is an orally available drug candidate that is in Phase 2 clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator.

The company’s second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. The former is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase 2 development for the treatment of patients with hypercholesterolemia and fatty liver disease.

H.C. Wainwright has a massive $31 price target, which compares the posted consensus target of $24.30. The shares closed on Friday at $7.15.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

These are five stocks for aggressive accounts looking to get share count leverage on companies with sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage on them. Note though that while markets again near all-time highs, value stocks come with some risks.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.